Race Oncology : RAC Quarterly Investor Presentation

only RNA-DIRECTED THERAPEUTICS

useTO TREAT CANCER AND PROTECT THE HEART

ersonalQuarterly Investor Update Presentation

Authorised for release by Phillip Lynch CEO & MD on July 27, 2022

DISCLAIMER

Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race

onlyi to account the investment objectives, financial situation and particular needs of the investor. Before making any investment in Race, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary. This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development

does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This

presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take

useand therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such tatements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive

	regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from
ersonal
	those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements.
	Consideration should be given to these and other risks concerning research and development programs referred to in this
	presentation.
	RACE ONCOLOGY LIMITED (ASX:RAC)		2		INVESTOR PRESENTATION

CORPORATE SNAPSHOT

				ASX 24 MONTH PERFORMANCE
	ISSUED CAPITAL
only	159.5m
	Shares1
	Options1	13.4m
	Shareholders2	9,302
	MARKET CAPITALISATION
use	$2.17
	Share price1
	Market value1	$355.7m
	Cash2	$33.5m
	Enterprise value	$322.2m
	SIGNIFICANT SHAREHOLDERS
ersonal	8.5%
	Dr Daniel Tillett (Director & CSO)
	Dr John Cullity (Chairman)	5.1%
	Merchant Opportunities Fund	4.8%

1. As at 26	July 2022.
2. As at 30	June 2022
RACE ONCOLOGY LIMITED (ASX:RAC)		3		INVESTOR PRESENTATION

onlyuseQUARTERLY HIGHLIGHTS ersonal

1 ZANTRENE® CLINICAL PHASE 1B - R/R AML STATUS

only	2020 Phase 2 trial demonstrated an impressive 40% overall
response rate for Zantrene as a single agent in R/R AML1
		CURRENT R/R AML PHASE 1B/2 TRIAL
		• Phase 1b/2 combination study in up to 29 R/R AML patients
use		(NCT04989335)
• Regimen. Zantrene + fludarabine + clofarabine
•	2022
		PI. Prof Arnon Nagler, Chaim Sheba, Israel
		• First patient treated Aug. 2021, Phase 1b completed in May.
ersonal	PHASE 1B TRIAL HIGHLIGHTS
•	Encouraging clinical responses in heavily pre-treated patients:
			3/6 patients successfully bridged to stem cell transplant
		• Now advancing to Phase 2 - efficacy stage
		• Open label study results to be reported in stages
	1. Canaani J et al. A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia Eur J Haematol. 2020;00:1-7.
	RACE ONCOLOGY LIMITED (ASX:RAC)			5

INVESTOR PRESENTATION